A Two-year, Randomized, Controlled, Open-label, Virologic Response Adaptive Design, Multicenter Study to Optimize Antiviral Efficacy of Telbivudine in Adult Patients With HBeAg Positive Chronic Hepatitis B (EFFORT Study).

Trial Profile

A Two-year, Randomized, Controlled, Open-label, Virologic Response Adaptive Design, Multicenter Study to Optimize Antiviral Efficacy of Telbivudine in Adult Patients With HBeAg Positive Chronic Hepatitis B (EFFORT Study).

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Telbivudine (Primary) ; Adefovir
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms EFFORT
  • Most Recent Events

    • 02 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.(Parent trial: NCT00962533).
    • 10 Feb 2012 An extension study was initiated in August 2011 (ClinicalTrials.gov, NCT01529255).
    • 16 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top